(Q39151581)

English

Enhanced killing of ovarian carcinoma using oncolytic measles vaccine virus armed with a yeast cytosine deaminase and uracil phosphoribosyltransferase

scientific article published on 12 May 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Enhanced killing of ovarian carcinoma using oncolytic measles vaccine virus armed with a yeast cytosine deaminase and uracil phosphoribosyltransferase (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

1 reference

based on heuristic

inferred from title

oncolytic virus

1 reference

based on heuristic

inferred from title

ovarian carcinoma

1 reference

based on heuristic

inferred from title

measles vaccine

1 reference

based on heuristic

inferred from title

author name string

A D Hartkopf

1

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

S Bossow

2

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

J Lampe

3

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

M Zimmermann

4

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

F-A Taran

5

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

D Wallwiener

6

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

T Fehm

7

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

M Bitzer

8

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

U M Lauer

9

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

language of work or name

0 references

publication date

12 May 2013

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

130

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

362-368

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.004

7 January 2021

Rethinking ovarian cancer: recommendations for improving outcomes

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.004

7 January 2021

Oncolytic virotherapy of gynecologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.004

7 January 2021

Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.004

7 January 2021

Oncolytic virus as an agent for the treatment of malignant ascites

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.004

7 January 2021

Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.004

7 January 2021

Preclinical testing of virotherapeutics for primary and secondary tumors of the liver

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.004

7 January 2021

Innate immune defense defines susceptibility of sarcoma cells to measles vaccine virus-based oncolysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.004

7 January 2021

New colorimetric cytotoxicity assay for anticancer-drug screening

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.004

7 January 2021

Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.004

7 January 2021

Current overview of the pathogenesis and prophylaxis of measles with focus on practical implications

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.004

7 January 2021

A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.004

7 January 2021

5-fluorouracil and low-dose leucovorin in the treatment of recurrent squamous cell carcinoma of the cervix. A phase II trial of the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.004

7 January 2021

Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.004

7 January 2021

Experimental models of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.004

7 January 2021

Maximizing mouse cancer models

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.004

7 January 2021

Oncolytic virotherapy of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.004

7 January 2021

Identifiers

10.1016/J.YGYNO.2013.05.004

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39151581&oldid=1809665085"